During the past decade, Byers Eye Institute at Stanford conducted 50 clinical trials. In the 10-year time frame, 50 clinical trials started and 17 clinical trials were completed, i.e. on average, 34% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 17 clinical trials were completed. i.e. 85% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Byers Eye Institute at Stanford" #1 sponsor was "Stanford University" with 18 trials, followed by "Apellis Pharmaceuticals, Inc." with 3 trials sponsored, "Aura Biosciences" with 3 trials sponsored, "Gyroscope Therapeutics Limited" with 3 trials sponsored and "Hoffmann-La Roche" with 3 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Byers Eye Institute at Stanford" #1 collaborator was "Novartis Pharmaceuticals" with 3 trials as a collaborator, "NYU Langone Health" with 2 trials as a collaborator, "Otto-von-Guericke University Magdeburg" with 2 trials as a collaborator, "Stanford University" with 2 trials as a collaborator and "Alcon Vision" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Byers Eye Institute at Stanford" are "Glaucoma" (8 trials), "Geographic Atrophy" (5 trials), "Diabetic Macular Edema" (4 trials), "Dry Age-related Macular Degeneration" (4 trials) and "Myopia" (4 trials). Many other conditions were trialed in "Byers Eye Institute at Stanford" in a lesser frequency.

Most popular intervention types in "Byers Eye Institute at Stanford" are "Drug" (38 trials), "Device" (11 trials), "Other" (10 trials), "Procedure" (5 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Sham Procedure" (4 trials), "KSI-301" (2 trials), "Lampalizumab" (2 trials) and "NT-501" (2 trials). Other intervention names were less common.

The vast majority of trials in "Byers Eye Institute at Stanford" are 54 trials for "All" genders.

Currently, there are NaN active trials in "Byers Eye Institute at Stanford". undefined are not yet recruiting, 13 are recruiting, 10 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 19 completed trials in Byers Eye Institute at Stanford, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Byers Eye Institute at Stanford, 7 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 9 trials that are defined as “Not Applicable".